Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repligen Corporation's SEC filings document financial reporting, governance and public-company capital structure for a Nasdaq-listed life sciences company in bioprocessing technology. Recent Form 8-K reports attach earnings releases for quarterly and annual results, financial guidance and non-GAAP measures such as organic revenue, adjusted operating income, adjusted EPS and adjusted EBITDA.
The filing record also includes definitive proxy materials covering board matters, executive compensation and equity awards, along with Form 8-K disclosures on officer appointments, principal accounting officer responsibilities, financial reporting oversight and Sarbanes-Oxley-related infrastructure. Securities registration disclosures identify RGEN common stock, par value $0.01 per share, on the Nasdaq Global Select Market.
Repligen Corporation CFO Jason K. Garland reported equity compensation awards consisting of stock options and restricted stock units. He received 8,315 stock options with an exercise price of $141.91 per share, expiring on March 5, 2036, which vest in three equal annual installments on March 5, 2027, March 5, 2028, and March 5, 2029. He was also granted 7,751 restricted stock units, vesting in equal annual installments over three years beginning on the first anniversary of the grant date, each unit representing one share of common stock. Following the award, his direct common stock holdings total 20,092 shares.
Repligen Corp Chief Operating Officer James Bylund reported routine equity compensation activity. He acquired 125 shares of common stock at no cost upon the release of a Performance Stock Unit award tied to pre-established performance criteria, and 62 shares were withheld to cover related tax obligations. After these transactions, he directly holds 17,672 common shares.
Repligen Corp Senior VP R&D Ralf Kuriyel reported equity compensation activity involving common stock. He acquired 125 shares at no cost upon vesting of a previously granted performance stock unit award, after the company met pre-set performance goals. To cover related tax obligations, 42 shares were disposed of and withheld by the company, leaving him with 14,778 directly owned shares.
Repligen Corporation’s Chief Operating Officer James Bylund reported two share dispositions that were automatically used to cover taxes on vesting stock awards, rather than open-market sales. On February 27, 2026, 1,478 common shares at $128.73 per share were withheld, and on March 2, 2026, 2,433 shares at $124.97 per share were withheld.
These shares were retained by the company to satisfy Bylund’s tax withholding obligations triggered by the release of restricted stock units. After the March 2 withholding, Bylund directly owned 17,609 Repligen common shares.
Repligen Corp Chief Executive Officer Olivier Loeillot reported two Form 4 transactions where shares were withheld to cover taxes on restricted stock units. On February 27, 2026, 344 shares of common stock were disposed of at $128.73 per share, leaving 35,554 shares directly owned. On March 2, 2026, 1,610 shares were disposed of at $124.97 per share, leaving 33,944 shares directly owned. These are tax-withholding dispositions, not open-market sales.
REPLIGEN CORP director Anthony Hunt reported a tax-related share disposition. On the release of restricted stock units, 9,897 shares of common stock were withheld by the company to cover his tax withholding obligations at a reference price of $124.97 per share. After this non‑open‑market transaction, he directly owned 89,062 shares.
Repligen Corporation’s CFO Jason K. Garland reported routine tax-related share withholdings. On March 2, 2026, the company withheld 715 shares of common stock at $124.97 per share, and on February 27, 2026, it withheld 327 shares at $128.73 per share to satisfy tax obligations triggered by restricted stock unit releases. These dispositions were for tax withholding rather than open-market sales.
Repligen Corp senior vice president of R&D Ralf Kuriyel reported two tax-related share dispositions. On February 27, 2026, the company withheld 444 shares of common stock at $128.73 to cover tax obligations from restricted stock units vesting.
On March 2, 2026, the company similarly withheld 923 shares at $124.97. After the later transaction, Kuriyel directly owned 14,695 common shares. These were tax-withholding events rather than open-market sales.
Repligen Corp chief product officer Brian Robb reported a small share disposition tied to taxes rather than an open-market trade. On the reported date, 221 shares of common stock were withheld by the company at $124.97 per share to cover tax obligations arising from the release of restricted stock units. After this tax-withholding transaction, Robb’s directly held common stock balance was 8,319 shares.
Repligen Corporation provides an annual overview of its global bioprocessing business, describing franchises in filtration, chromatography, process analytics and proteins that serve biologics and emerging gene and cell therapy markets. The company estimates a roughly $13 billion addressable market within a $20 billion global bioprocessing space.
Repligen highlights growth via innovation, integrated solutions and targeted acquisitions, including the 2025 purchase of 908 Devices’ bioprocess PAT portfolio, while operating 19 manufacturing sites and employing about 2,000 people worldwide. The filing also outlines key risks, such as customer and supplier concentration, competition, foreign exchange exposure, $600 million of 1.00% convertible notes due 2028 and material weaknesses in internal controls.